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It is largely unknown whether hepatitis B virus (HBV) sequence variation during chronic infection hampers HBV immune
recognition or the antiviral effect of cytokines on HBV production. Here we have analyzed which region of the HBV genome
changes most drastically during an interferon-a (IFNa)-stimulated immune response. In addition, we have investigated
whether the mutations affect viral replication, gene expression, and immune recognition of the mutant viral proteins. The
study was performed with full-length HBV genomes taken longitudinally from a patient who transiently cleared HBV and
seroconverted to anti-HBe during a long-term IFNa treatment. We found a replacement of the predominant virus population
during IFNa therapy. The virus populations differed mainly by a cluster of nucleotide changes in the C-gene and a pre-S2
deletion. Most of the newly emerging mutations localized within core/HBe B-cell epitopes, changed HBe antigenicity toward
mono- and polyclonal antibodies, and also influenced the reactivity of the anti-HBc/e antibodies of the patient. All genomes
tested expressed less HBeAg than wild-type HBV, while replication and IFNa susceptibility were similar. These data indicate
that IFNa therapy can lead to the emergence of HBV variants with mutations mainly affecting recognition of the core/HBe
proteins by antibodies. Taken together, the type of core/HBe-specific B-cell immune response, the sequence of the
corresponding epitopes, and the HBe expression level appear to contribute to the decision on viral clearance or persistence.
© 1998 Academic Press
INTRODUCTION
Hepatitis B virus (HBV) infection is associated with a
variety of clinical manifestations ranging from acute ful-
minant to chronic hepatitis, liver cirrhosis, up to the
development of hepatocellular carcinoma. Replication of
wild-type HBV is noncytopathic and hepatitis is believed
to be mainly, if not exclusively, the result of the corre-
sponding immune response. HBV is targeted by the
immune response at several levels. Antibodies are pro-
duced against all known proteins of the virus, namely,
against surface proteins (anti-HBs), the nucleocapsid
(anti-HBc), the e antigen (anti-HBe), and against the poly-
merase and X protein. Furthermore, core and e proteins
(HBc and HBe, respectively), surface, and polymerase
proteins are targets for cytotoxic T-cells (CTL) and/or
T-helper cells (Chisari and Ferrari, 1995). The T-cell re-
sponse seems to be important for virus clearance in vivo,
as it is activated during acute self-limited hepatitis but is
almost completely absent during chronic hepatitis (Fer-
rari et al., 1990; Jung et al., 1991; Penna et al., 1991;
Rehermann et al., 1995). Recent evidence obtained with
HBV-transgenic and natural animal models, as well as
cell culture systems, suggests that noncytolytic cytokine-
mediated inactivation of viral gene expression and rep-
lication could play a dominant role in hepadnavirus
clearance (Hayashi and Koike, 1989; Jilbert et al., 1992;
Kajino et al., 1994; Tsui et al., 1995; Guidotti et al., 1996).
Sequence variation is one of the most powerful viral
strategies for escaping recognition by the host’s immune
system which can facilitate virus persistence. HBV se-
quence heterogeneity has been intensively studied in the
recent years and many of the changes observed were
suggested to be selected by the immune response. In-
vestigations particularly focused on the C-gene as one of
the targets. The C-gene encodes two viral proteins, the
HBc and HBe proteins. HBc is the building block of the
viral nucleocapsid and HBe is a secretory protein with
presumed function in the establishment of chronic infec-
tion (Milich et al., 1990). Pre-C variants in which transla-
tion of HBe is prevented by mutations in the precore
region are characteristic mainly of anti-HBe-positive pa-
tients (Brunetto et al., 1991). They emerge frequently
around the time of spontaneous or interferon-a (IFNa)-
induced HBeAg-to-anti-HBe seroconversion (Okamoto et
al., 1990; Gu¨nther et al., 1992). As these events are
associated with increasing recognition of HBe on both
the T-helper cell and B-cell levels (Tsai et al., 1992;
Maruyama et al., 1993), selection of pre-C variants was
suggested to be triggered by the immune response.
Reduced synthesis of HBe due to mutations in the C-
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gene promoter (Okamoto et al., 1994; Buckwold et al.,
1996; Gu¨nther et al., 1996) may be another way the virus
could downregulate HBe immune recognition. In addi-
tion, amino acid changes in HBe and HBc were reported
to be associated with severe chronic liver disease and it
has been speculated that B- and T-cell epitopes are
affected (Ehata et al., 1992; Carman et al., 1997). In fact,
reduced CTL recognition of a mutated HBc/e CTL
epitope was observed in two patients with a strong CTL
response narrowly focused to this epitope (Bertoletti et
al., 1994). In contrast, another study indicated that es-
cape from CTL response is, if at all, an unusual event in
patients with chronic hepatitis (Rehermann et al., 1995).
IFNa treatment can promote virus clearance most
likely via immune stimulation and direct cytokine-medi-
ated suppression of HBV replication. However, it is ef-
fective only in a proportion of patients and the mecha-
nisms underlying nonresponse and relapse after tran-
sient response are not understood. One might speculate
that HBV strains with reduced susceptibility to interfer-
ons and other antiviral cytokines exist prior to or emerge
during IFNa therapy and account for virus persistence.
This idea is supported by the observation that particular
strains of measles, herpes simplex, and lymphocytic
choriomeningitis virus are resistant to interferon and
have an increased tendency to establish virus persis-
tence (Carrigan and Kehl-Knox, 1990; Su et al., 1990;
Moskophidis et al., 1994). Taken together, it is largely
unknown whether HBV ‘‘escapes’’ recognition by T-helper
cells, CTLs, antibodies, or cytokine-mediated effects and
which role sequence variation plays in this respect.
Since most studies have focused on single HBV genes,
it is even elusive which of the HBV gene products dis-
plays the highest degree of variation during chronic
infection and IFNa therapy.
This study aimed at identifying those HBV gene prod-
ucts which are most variable during IFNa-stimulated
immune response and at elucidating the possible rele-
vance of the corresponding changes for the immune
recognition of the virus. We addressed this question by
longitudinally analyzing the structure and function of sev-
eral complete HBV genome populations isolated from a
patient who was treated for more than 1 year with IFNa,
seroconverted to anti-HBe, cleared the virus from circu-
lation without selecting for pre-C variants, and experi-
enced a relapse of viremia (Gu¨nther et al., 1992). The
reactivity of antibodies with the corresponding HBe pro-
teins and core/HBe peptides was tested and it was
analyzed in vitro whether the patient selected IFNa-
resistant HBV strains during the long-term IFNa therapy.
RESULTS
Clinical, histopathological, and serological data of the
patient
Initially, the patient studied was HBsAg- and HBeAg-
positive and had histologically proven chronic active
hepatitis (CAH) (Fig. 1). He was treated for 12 months
with IFNa, which induced HBeAg-to-anti-HBe serocon-
version and cleared serum HBV DNA below 10 genomes/
FIG. 1. Clinical, serological, and histological course of chronic hepatitis B of the patient. IFNa treatment periods, histological diagnoses, and the time of
HBV analysis are indicated. CAH, chronic active hepatitis; ALT, alanine aminotransferase (dashed line); HBV DNA concentration in serum (solid line).
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ml. After cessation of treatment viremia rapidly rose to
high titers. The patient was again treated for 4 months
with IFNa but viremia decreased only to 104 HBV ge-
nomes/ml even after increasing the IFNa dosis. After the
end of treatment high viremia relapsed again and per-
sisted for years. Although pre-C-defective variants were
neither present nor emerged the serum remained
HBeAg-negative (Gu¨nther et al., 1992). Immune-com-
plexed HBeAg could be found only in the most highly
viremic serum sample December of 1990 but not in the
others using a test (Miles et al., 1993) that detects im-
mune complexes in a 1:100 dilution of a HBeAg-positive
serum in an excess of anti-HBe (Table 1). In conclusion,
seroconversion to anti-HBe and transient clearance of
HBV from circulation indicate an efficiently stimulated
immune response during the long-term IFNa treatment.
The rapid relapse of viremia and its persistence at a high
level despite of anti-HBe and IFNa retreatment are un-
common (Hoofnagle et al., 1981; Gu¨nther et al., 1992) and
suggest the presence or selection of a virus variant with
an unusual tendency to establish virus persistence.
Structural features of the full-length HBV genomes
HBV populations in serum samples before (June 1989)
and after (January 1991) the first IFNa treatment, as well
as 5 months (July 1991) and 2 years (April 1993) after the
second IFNa treatment were analyzed (Fig. 1). Full-
length HBV genomes were amplified and separated in
ethidium bromide-stained agarose gels. Only fragments
of wild-type genome length (3.2 kb) were seen (data not
shown) indicating that HBV variants with large deletions
were neither present nor emerged during the follow-up
as a major virus population. The 3.2-kb genomes of the
virus populations were directly sequenced in their entire
length and structural characteristics were analyzed by
comparison with the most closely related genome of
genotype D (designated wild-type in the following) (Gali-
bert et al., 1979). All four genome populations shared 104
nucleotide differences compared to wild-type HBV,
whereas 23 nucleotide differences and a deletion were
detected only in some of them (Fig. 2). The transcrip-
tional regulatory regions, except the core promoter/en-
hancer II (Cp/EnII), were rather conserved. Specifically,
mutations T(1753)3C, G(1757)3A, A(1762)3T, and G(1764)3A
clustered within transcription factor binding sites of the
basic core promoter (Raney et al., 1997) and a C(1653)3T
change was found in the C/EBP binding site of the
activating a box element of Cp/EnII (Fig. 2) (Lo´pez-Ca-
brera et al., 1990; Yuh and Ting, 1991; Yuh et al., 1992).
The encapsidation signal differed from that of wild-type
HBV only by a G(1899)3A change which is compatible
with its function (Hasegawa et al., 1994; Yuan et al., 1995;
Miska, 1996). The same mutation leads to a glycine to
aspartate change in the ultimate codon (codon 29) of the
pre-C region. Elements important for replication (DR1
and DR2) and all known open reading frames were
preserved, but predicted protein sequences differed in
some positions from those of the wild-type virus (Fig. 3A).
Two amino acid changes in the first loop of the a deter-
minant of HBsAg and three in the C-terminal ‘‘transacti-
vation’’ domain of the X protein (Arii et al., 1992) may have
implications for the antigenicity and function of the re-
spective proteins.
Sequence changes in the HBV genome population
during follow-up
The dominant HBV genome population changed at 21
positions during the IFNa treatment period June 1989 to
January 1991 (Fig. 3B). The changes observed cluster in
the C-gene and 59 end of the P-gene. In contrast to the
mutations in the P-gene all mutations in the C-gene
result in amino acid substitutions in the core protein and
e antigen. Remarkably, the only change observed in the
pre-S1/2 regions was the disappearance of an in-frame
deletion in the pre-S2 region present in 50% of all mole-
cules in June 1989. Except for two amino acid changes at
its very N- and C-termini, the S-protein domain was also
highly conserved. No changes were seen in the X-gene
and 39 end of the P-gene. The point mutations at most
positions (n 5 12) were already present in 10–50% of the
genomes from serum in June 1989 and their prevalence
increased by about 50% during IFNa therapy. De novo
emergence of mutations was observed only at 8 posi-
tions, and 6 of them were located in the C-gene at
positions 1961, 1962, 2129, 2149, 2160, and 2172. Except
for one additional mutation at position 2937, the virus
population remained largely unchanged between the
time period January 1991 (1/91) to July 1991 (7/91). In
contrast, during 7/91 and April 1993 (4/93) the virus
population changed again at several positions. Interest-
TABLE 1
Detection of HBeAg in Immune Complexes
Samples
Glycine
treatment
HBeAg
(S/N)
Patient
Serum 12/90 1 4.7 6 0.1
Serum 01/91 1 1.3 6 0.1
Serum 02/91 1 1.5 6 0.1
Serum 03/91 1 1.8 6 0
Serum 07/91 1 2.0 6 0
Serum 04/93 1 1.4 6 0.3
Controlsa
HBeAg (1:10) 1 anti-HBe 2 1.0
HBeAg (1:10) 1 anti-HBe 1 65.8 6 5.6
HBeAg (1:100) 1 anti-HBe 2 1.0
HBeAg (1:100) 1 anti-HBe 1 3.2 6 0.3
Note. Mean and SD are given when experiments were done in
duplicate. S/N, signal to noise ratio.
a HBeAg and anti-HBe from a pool of HBeAg-positive and anti-HBe-
positive sera, respectively, were mixed as indicated and incubated at
4°C for 2 days prior to analysis.
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ingly, the dominant genome population was nearly iden-
tical with the initial population in serum in June 1989
(6/89). Only two novel mutations at positions 2357 in the
C-gene and 1766 in the X-gene/core promoter emerged.
With the exception of amino acid exchanges at positions
108, 211, and 470 in the P protein and the deletion in
pre-S2 all other mutations were located outside of po-
tential CTL epitopes restricted to the patient’s HLA-A1
and B8 type. This analysis shows that the C-gene was
the hot spot for mutations during IFNa therapy, specifi-
cally for those emerging de novo which lead to amino
acid changes. Remarkably, the initial virus population
was not completely eliminated but reemerged as the
dominant population after cessation of treatment.
HBc/e sequences of individual molecules
Because mutations identified by direct sequencing
were predominantly in the C-gene, their distribution was
analyzed in detail by sequencing of 21 cloned C-gene
fragments derived from sera 6/89 and 1/91. As all nucle-
otide changes in the C-gene resulted in amino acid
FIG. 3. Sequence analysis of the HBV populations isolated from the patient during follow-up. (A) Amino acid changes shared by all four HBV genome
populations in comparison to the wild-type HBV (Galibert et al., 1979) gene products. Each difference is shown in one-letter codes within the HBV
genes (C, S, X, and P; black dots indicate start codons). The a determinant of HBsAg (a), the transactivation domain of X protein (TA), and the priming
tyrosine (Y) and the active site of the reverse transcriptase (YMDD) of the P protein are indicated. (B) Sequential nucleotide and amino acid changes
in the HBV genome population during follow-up. A sequence that shares most characteristics of HBV genomes from 6/89 is defined as a reference
sequence (‘‘reference’’). This reference sequence differs from the wild-type sequence (Galibert et al., 1979) at positions 532, 766, 895, 2339, 2340, 2570,
2628, 2651, 2660, and 2705 in addition to the differences that are common to all analyzed HBV populations (Fig. 2). Nucleotide changes in comparison
to the reference sequence (‘‘change’’) are shown as vertical bars in the upper part of the figure. The presence of a deletion is shown as a box. Vertical
arrows indicate corresponding amino acid changes which are given in one-letter codes within the respective genes. In the lower part of the figure
the frequency of a particular mutation in the genome population is indicated in percentage as estimated from the signal intensities at heterogeneous
positions in the sequence autoradiograph. The characteristic sequences of 6/89 and 1/91 have been sent to GenBank and assigned the Accession
numbers AF043593 and AF043594, respectively.
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changes, the sequences were compared on the level of
the HBc/e primary sequence (Fig. 4). The prevalence of
the mutations in the clones was consistent with that
estimated from the direct sequence analysis and were
distributed on single molecules as follows. Three types
of HBc/e molecules were found in serum 6/89: the first
was characterized by amino acids E(14) and C(147) (HBe
variant 2), the second by Q(14) and T(147) (HBe variant 6),
and the third by Q(14) and C(147) (HBe variant 4). In the
HBc/e molecules from serum 1/91 amino acids Q(14) and
T(147) became dominant (.90% of all clones) and five
additional amino acid changes (S(21)3H, E(77)3Q,
D(83)3E, S(87)3T, and T(91)3I) emerged de novo. Be-
cause of their specific distribution these five exchanges
generate four novel yet different types of HBc/e mole-
cules characterized by amino acid H(21) alone (HBe vari-
ant 10), H(21) and T(87) (HBe variant 14), Q(77) and T(87)
(HBe variant 16), and E(83) and I(91) (HBe variant 18). Only
one clone showed a sequence pattern identical to one of
those before IFNa therapy (HBe variant 9). Taking the
changes at positions 14 and 147 into account, six major
types of HBc/e molecules were found in serum 1/91. In
summary, a quasispecies-like population of HBc/e mol-
ecules was selected during IFNa therapy and nearly
completely replaced the initial HBc/e protein population.
Expression and antigenicity of HBe variants
The mutations selected in the HBe molecules may
have consequences for synthesis, secretion, and/or an-
tigenicity of HBeAg. In order to test these possibilities,
the most prevalent HBe types before (Fig. 4, HBe variants
2 and 6 from 6/89) and after (Fig. 4, HBe variants 10, 16,
and 18 from 1/91) the first IFNa treatment course were
transiently expressed in HuH7 cells under CMV pro-
moter control. When measured by an assay based on
polyclonal anti-HBe (Abbott), HBe variants from both clin-
ical phases were detected at high levels in the superna-
tants of the transfected cells (Fig. 5, assay A), indicating
that the pre-C/C-gene mutations do not prevent HBeAg
synthesis and secretion.
Next we analyzed whether the amino acid substitu-
tions could change HBc/e T- and B-cell antigenicity. Se-
quence changes in potential T-cell epitopes were inves-
tigated by computer programs and the antigenicity of
HBe was tested experimentally. None of the HBc/e
amino acid changes were located within potential
HLA-A1 or B8-restricted CTL epitopes and only the
change at position 14 was located within a peptide se-
quence previously shown to stimulate T-cells with MHC
class II markers HLA-DR3, DR52, DQ2 (Ferrari et al.,
1991), the same as in our patient (Fig. 4). In contrast, four
of the five de novo mutations were located within the
HBc/e1 B-cell epitope (Fig. 4) (Salfeld et al., 1989). Fur-
thermore, the N- and C-terminal mutations may affect the
HBe2 B-cell epitope (Salfeld et al., 1989).
To test whether these mutations indeed changed HBe
B-cell antigenicity, HBeAg levels in the culture media of
cells transfected with HBe expression constructs were
measured using three assays based on different poly-
clonal and monoclonal anti-HBe for detection (Fig. 5,
assays A–C). Compared to HBe variants 2, 6, and 10 the
antigenicity of variants 16 and 18, the only ones which
contain mutations in the HBe1 epitope, is drastically
different. They were detected at intermediate or high
levels in the polyclonal assay A, at reduced levels in
assay B but not at all in assay C, whereas the interassay
differences for the other variants were much smaller.
Since assays B and C use the same conjugated mAb for
detection, the lack of reactivity in assay C is due to the
failure of the HBc/e1 epitope-specific mAb[4] to bind to
the mutant HBe1 epitope of HBe variants 16 and 18.
Minor differences in HBe antigenicity were also evident
for variants 6 and 10 (Fig. 5, compare reactivities in assay
B with assay C). Taken together, these data show that
two of the three major HBe variants selected during IFNa
treatment differ in B-cell antigenicity from both major
HBe species present before therapy.
Recognition of the HBe variants by anti-HBe of the
patient
Using an inhibition assay it was tested whether the
mutations also influence reactivity of anti-HBe antibodies
in the patient’s sera. Anti-HBe-positive sera 12/90, 1/91,
7/91, and 4/93 even if diluted 1:50–1:100 competed effi-
ciently with polyclonal anti-HBe on the solid phase for
binding to all HBe variants (Fig. 6A and data not shown).
This indicates that the mutations in HBe do not prevent
binding of the polyclonal anti-HBe antibodies of the pa-
tient. Next, we wondered whether some sera bind more
efficiently to a specific HBe variant than to other variants.
For each serum the reactivity with one variant was ana-
lyzed relative to the reactivity with another variant by
forming the ratio of the corresponding HBeAg fractions
detected on the solid phase (FHBe ratio). As exemplified
in Fig. 6A for binding of sera 7/91 and 4/93 to HBe
variants 2 and 18, different FHBe ratios reflect different
specificity of the corresponding sera. Thus, the decrease
of the FHBe10/FHBe2 and FHBe10/FHBe6 ratios from 12/90 to
4/93 (Fig. 6B) indicates that HBe variant 10 became
increasingly better recognized relative to HBe variants 2
and 6 during the course of infection. Similarly, recogni-
tion of HBe variant 18 increased relative to variants 2 and
6 between 1/91 and 7/91 but then decreased from 7/91 to
4/93 (Fig. 6B). Changes in recognition also occurred
during 12/90 and 4/93 among all three HBe variants
selected during IFNa therapy (HBe variants 10, 16, 18)
(Fig. 6C). The FHBe ratios among variants 2, 6, and 16
remained unchanged (data not shown). In summary, the
specificity of the dominant anti-HBe population shifts
with time, which indicates that most HBe variants are
recognized by a specific subset of anti-HBe. This implies
that the amino acid changes which emerged in HBe
151HBV POPULATIONS DURING IFNa THERAPY
FI
G
.4
.H
B
c/
e
am
in
o
ac
id
se
qu
en
ce
s
of
21
cl
on
ed
C
-g
en
es
is
ol
at
ed
be
fo
re
(6
/8
9)
an
d
af
te
r
(1
/9
1)
IF
N
a
th
er
ap
y.
Th
e
pr
ed
om
in
an
t
se
qu
en
ce
of
th
e
ge
no
m
e
po
pu
la
tio
n
fr
om
6/
89
as
de
te
rm
in
ed
by
di
re
ct
se
qu
en
ci
ng
(F
ig
.3
B
)
is
sh
ow
n
ab
ov
e
th
e
al
ig
nm
en
t
(‘‘6
/8
9’
’).
C
ha
ng
es
de
te
ct
ed
by
di
re
ct
se
qu
en
ci
ng
ar
e
bo
xe
d.
N
-
an
d
C
-te
rm
in
io
f
th
e
di
ffe
re
nt
C
-g
en
e
pr
od
uc
ts
ar
e
m
ar
ke
d
by
ar
ro
w
s.
P
ut
at
iv
e
C
TL
ep
ito
pe
s
sp
ec
ifi
c
fo
r
th
e
M
H
C
cl
as
s
I
ty
pe
of
th
e
pa
tie
nt
(H
LA
-A
1
an
d
B
8)
,p
ep
tid
e
se
qu
en
ce
s
pr
ev
io
us
ly
sh
ow
n
to
st
im
ul
at
e
T-
ce
lls
w
ith
th
e
M
H
C
cl
as
s
II
ty
pe
of
th
e
pa
tie
nt
st
ud
ie
d
he
re
(H
LA
-D
R
3,
D
R
52
,a
nd
D
Q
2)
(F
er
ra
ri
et
al
.,
19
91
),
an
d
th
e
B
-c
el
l
ep
ito
pe
s
of
H
B
cA
g
as
w
el
l
as
H
B
eA
g
(S
al
fe
ld
et
al
.,
19
89
)
ar
e
in
di
ca
te
d
(H
B
c
an
d
H
B
e1
/H
B
e2
,
re
sp
ec
tiv
el
y)
.
H
B
e
va
ria
nt
s
us
ed
fo
r
im
m
un
ol
og
ic
al
st
ud
ie
s
ar
e
en
ci
rc
le
d.
152 GU¨NTHER ET AL.
variants 10 and 18 during IFNa therapy influence binding
of the patient’s anti-HBe antibodies. This also corrobo-
rates the data obtained with mAbs that these mutations
change HBe antigenicity.
Recognition of HBc/e1 epitope peptides by anti-HBc/
anti-HBe of the patient
To further substantiate these findings the binding of
the patient’s anti-HBc as well as anti-HBe to HBc/e pep-
tides (residues 69–99) covering wild-type or mutant
HBc/e1 epitopes was measured in a direct assay. In
agreement with the competitive assay, the wild-type pep-
tide 1 (derived from HBc/e molecules 2 and 6) and the
mutant peptides 2 and 3 (derived from HBc/e molecules
16 and 18, respectively) were recognized by sera of the
patient that were either positive for anti-HBc alone (6/89)
or positive for anti-HBc and anti-HBe (12/90, 3/91, and
4/93). However, compared to the wild-type peptide, bind-
ing to the mutant peptides was reduced (Fig. 7). For sera
12/90 and 3/91, the summary of independent experiments
revealed a reduction of the S/N ratios by factors of about
2 and 6 for mutant peptides 2 and 3, respectively (Fig.
7B). An anti-HBe-positive control serum bound only the
wild-type but not the mutant peptides (Fig. 7A). Further-
more, each peptide showed a specific and reproducible
reaction pattern with the sera tested which differed only
between wild-type peptide 1 and mutant peptide 3. This
is consistent with the shift in recognition that was ob-
served in the competitive assay only for HBe variant 18
(peptide 3), but not HBe variant 16 (peptide 2), relative to
HBe variants 2 and 6 (peptide 1) (Fig. 6B). Taken together,
these data show that the HBc/e1 epitope is recognized
by the patient’s anti-HBc and anti-HBe antibodies and
that the mutations present in HBc/e variants 16 and 18
reduce their binding.
Characteristic features of HBV replication and gene
expression
Since the levels of HBe antigenemia and viremia result
from expression and replication of the mixture of different
genomes we tested whether the phenotype of the total HBV
genome population changed during IFNa treatment. Full-
length HBV genomes from sera 6/89, 1/91, 7/91, and 4/93 as
well as wild-type genomes (Galibert et al., 1979) were am-
plified by PCR and transfected into hepatoma cells without
prior cloning. The levels of replicative HBV DNA intermedi-
ates in these cells and of HBeAg in the cell culture medium
were found to be similar for HBV from the different clinical
stages (Figs. 8A, lanes IFNa2, and 8B). In contrast, the HBV
populations before IFNa therapy and 2 years after therapy
showed levels of HBsAg three to four times lower than
those of HBV selected during therapy (Fig. 8C). Compared
to wild-type HBV, all HBV populations from the patient had
5-fold lower levels of HBeAg and up to 10-fold lower levels
of HBsAg in the cell culture medium, although they pro-
duced similar or even slightly higher levels of intracellular
HBV DNA (Fig. 8). Taken together, all virus populations of
the patient were characterized by replication at wild-type
level but reduced expression of HBeAg and HBsAg in vitro.
Analysis of IFNa responsiveness of the HBV
population
We next tested in vitro whether the various structural
and functional changes in the HBV population, especially
those which occurred during the efficient IFNa stimula-
tion of the immune response, interfere with cytokine-
mediated reduction of intracellular viral replication and
gene expression (Hayashi and Koike, 1989; Tsui et al.,
1995; Guidotti et al., 1996). HuH7 cells were transfected
with amplified full-length HBV genome populations from
FIG. 5. Analysis of immune reactivity of HBe variants found before (HBe variants 2 and 6) and after (HBe variants 10, 16, and 18; for sequences see Fig.
4) IFNa therapy. The HBe variants were expressed in HuH7 cells and cell culture supernatants were analyzed by using different HBeAg immunoassays. For
assay A [HBe rDNA (Abbott)] polyclonal anti-HBe was used on solid phase and for detection, while in assays B and C polyclonal human anti-HBe (Organon
Teknika) and mAb anti-HBc/e[4] were on the solid phase, respectively, and peroxidase-labeled mAb anti-HBe[1] was used for detection.
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the patient and, as a control, with amplified wild-type
genomes and were treated with 500 U IFNa/ml medium
or were left untreated. Regardless of the type of HBV
genomes transfected, IFNa suppressed the levels of
intracellular replicative HBV DNA, HBeAg, and HBsAg by
about 80, 70, and 50%, respectively (Fig. 8A). Thus, none
of the structural or functional features of any of the
patient’s HBV populations interfere detectably with IFNa-
mediated intracellular inhibition of HBV.
DISCUSSION
In this study we analyzed the type, function, and im-
munological significance of mutations in HBV from a
long-term IFNa-treated patient. We found that the virus
populations present before, during, and after interferon
treatment were characterized by reduced HBeAg synthe-
sis. Furthermore, mutations emerged primarily in core/e
antigen, altered HBe B-cell antigenicity, and reduced
binding of corresponding antibodies of the patient. None
of the mutations in HBV from the patient detectably
affected susceptibility to IFNa. These data argue for a
possible role of the HBc/e B-cell response in virus elim-
ination in the patient studied.
All HBV proteins are known targets for the B- and
T-cell immune response (Chisari and Ferrari, 1995), and
mutations in any of the corresponding genes could con-
tribute to immune escape. We found amino acid changes
during IFNa therapy predominantly in the C-gene, in
particular those which emerged de novo in the HBV
population. Since IFNa obviously stimulated the immune
response against HBV in our patient, as reflected by
transient virus clearance and anti-HBe seroconversion
(Tsai et al., 1992; Maruyama et al., 1993), these data
suggest that the enhanced immune response selected
for mutations in the C-gene. In addition to the mutation
itself, the replacement of a rather homogenous C-gene
population by a quasispecies-like population may also
hamper HBc/e immune recognition. These interpreta-
tions are consistent with previous reports which point to
HBc/e as major immune targets (Ferrari et al., 1990, 1991;
Jung et al., 1991; Penna et al., 1991; Tsai et al., 1992) and
describe accumulation of mutations in HBc/e in patients
with active hepatitis (Ehata et al., 1992; Bertoletti et al.,
1994; Carman et al., 1997). However, in contrast to our
study, previously mutations in the C-gene were shown to
affect T-cell but not B-cell recognition of HBc/e (Bertoletti
et al., 1994). Based on our patient’s HLA type and on
computer predictions, most of the amino acid changes in
HBc/e are located outside of potential CTL and T-helper
cell epitopes. Although changed T-cell reactivity is thus
not excluded it is unlikely. In contrast, the HBe1 B-cell
epitope mapped between amino acid positions 75 and
90 (Salfeld et al., 1989) was clearly affected. The muta-
tions abrogated binding of a mAb and reduced binding of
antibodies in sera of the patient as well as in a heterol-
ogous serum. The reduced reactivity of the anti-HBc-
positive/anti-HBe-negative serum with the mutant pep-
tides suggest that also the overlapping epitope exposed
on core particles (HBcAg) is changed (Salfeld et al.,
1989). Furthermore, the amino acid change at position 21,
which only slightly influenced HBe antigenicity, may af-
fect the discontinuous HBe2 epitope which consists in
part of N-terminal HBe sequences (Salfeld et al., 1989). In
FIG. 6. Binding of anti-HBe in the patient’s sera to HBe variants ana-
lyzed by a competition assay. (A) Binding of HBe variants 2 and 18 to
polyclonal anti-HBe on the solid phase (IMx, Abbott) is inhibited by anti-
HBe in sera 7/91 and 4/93. The fraction of HBe bound by the solid phase
(FHBe) is shown on the y axis and the corresponding FHBe18/FHBe2 ratios
are indicated above the graphs. Note that the FHBe ratios are not influ-
enced by the absolute FHBe levels. (B) FHBe ratios between HBe variants
selected during IFNa therapy (HBe variants 10 and 18) and present before
therapy (HBe variants 2 and 6). Each column represents the mean and SD
of three independent determinations using 1:5 and 1:50 (serum 4/93) or
1:10 and 1:100 (sera 12/90, 1/91, and 7/91) serum dilutions. (C) FHBe ratios
among all HBe variants selected during IFNa therapy (HBe variants 10, 16,
and 18). Serum dilutions were as in B.
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conclusion, the observation that the mutations emerge
concomitant with IFNa-induced virus clearance and af-
fect binding of anti-HBe/anti-HBc antibodies make it con-
ceivable that the HBc/e-specific B-cell response contrib-
uted to virus elimination in the patient studied.
Although HBe and its precursor proteins are no inte-
gral components of the virion and the core particle is
embedded in a lipid shell, some studies indicate which
role HBe and HBc antibodies could play in immune
elimination. An anti-HBc mAb was reported to aggregate
virions suggesting that the HBc epitope can be exposed
on the surface of circulating Dane particles which may
facilitate virus neutralization (Mo¨ller et al., 1989). On the
other hand, HBe and duck hepatitis B e antigen and/or
their precursor proteins were shown to be accessible for
anti-HBe on the surface of hepatoma cells (Schlicht and
Schaller, 1989; Schlicht, 1991; Schlicht et al., 1991) and
woodchuck hepatitis B core/e reactivities were detected
in plasma membrane preparations from livers of infected
woodchucks (Michalak et al., 1990; Michalak and Lin,
1994). Therefore, cell toxicity may be activated by anti-
bodies binding to surface-exposed HBc/e as shown in
vitro using HBV-infected liver specimens (Michalak et al.,
1995). Most importantly, immunoglobulin preparations
containing anti-HBc and anti-HBe were reported to con-
fer protective immunity, implicating a role for these anti-
bodies in virus clearance in vivo (Stephan et al., 1984). It
is also conceivable that HBc/e B-cell epitopes are in-
volved in HBV elimination indirectly by a B-cell–T-cell
interaction mechanism described recently (Cooke et al.,
1994; Lenschow et al., 1994). After binding of antigen to
B-cell surface immunoglobulin (B-cell receptor), expres-
sion of costimulatory molecules on the B-cell, required
for amplification of the B- and T-cell immune response
and cytokine production (Linsley et al., 1991; He et al.,
1996), is triggered. A change of HBc/e antigenicity may
block signaling via the B-cell receptor and hence inter-
fere with activation of HBc/e-specific B- and T-cells and
cytokines.
Our analysis of the anti-HBe reactivity of follow-up sera of
the patient provides a first piece of information about
changes in anti-HBe specificities which can occur in rela-
tion to emergence of specific HBe variants. HBeAg is
known to elicit at least two non-cross-reactive anti-HBe
specificities (Imai et al., 1982; Salfeld et al., 1989). Since all
HBe variant proteins tested had only one of the two
epitopes mutated, their reactivity with anti-HBe in the pa-
tient’s sera is not surprising. However, specificity shifted
with time toward some of the mutant HBe proteins or
mutant HBc/e1 epitopes, which can be due to changing
FIG. 7. (A) Binding of anti-HBc/anti-HBe in sera 6/89, 12/90, 3/91, and 4/93 to peptides covering wild-type and mutant HBc/e1 epitopes (residues
69–99). Peptide 1 is derived from HBc/e sequences found before IFNa therapy (Fig. 4, sequences 2 and 6), and peptides 2 and 3 are derived from
mutant HBc/e sequences selected during therapy (Fig. 4, sequences 16 and 18, respectively). The amino acid changes in peptides 2 and 3 compared
to peptide 1 are indicated above the graphs. The absolute OD values were normalized with the background reactivity of the negative control serum
diluted 1/320 (OD 0.1–0.3). Pos., control serum positive for HBsAg, anti-HBc, and anti-HBe; Neg., control serum pool negative for HBsAg, anti-HBc, and
anti-HBe. (B) Mean and SD of S/N ratios (n 5 6) obtained with sera 12/90 and 3/91 in two independent experiments. Sera were diluted 1/160–1/640.
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concentration or affinity of specific anti-HBe subsets. These
findings demonstrate that changes in HBe antigenicity can
be accompanied by a change in anti-HBe populations.
Whether these fluctuating changes are causally related
with virus persistence remains to be studied.
Our study also provides a potential explanation for the
lack of serum HBeAg despite high viremia and absence
of pre-C-defective HBV. The HBV populations from all
sera of this patient were shown to produce less HBeAg
than wild-type HBV in vitro. This phenotype is in part
caused by reduced pre-C mRNA levels (Gu¨nther et al.,
1998), most likely mediated by mutations in the basic
core promoter region at positions 1753, 1757, 1762,
and/or 1764. Consistent with our study, mutations at
positions 1762 and 1764 were recently demonstrated to
lower pre-C mRNA and HBeAg levels (Buckwold et al.,
1996). However, reduced HBe synthesis cannot fully ac-
count for HBeAg seronegativity after therapy since HBV
with the same phenotype produced HBeAg before treat-
ment in vivo. Therefore, the lack of serum HBeAg must be
at least in part due to HBeAg/anti-HBe complex forma-
tion. Since we did not find such complexes in most of the
anti-HBe-positive sera they were probably rapidly
cleared in our patient. The reduced immune reactivity of
some of the mutant HBe proteins may also contribute to
the lack of HBeAg. Taken together, HBeAg seronegativity
in our patient probably results from reduced HBe syn-
thesis, low HBeAg immune reactivity, HBeAg/anti-HBe
immune complex formation, and their rapid clearance.
There were additional mutations present in HBV of the
patient which may be relevant for the clinical course. All
genomes contained a mutation in the pre-C region at po-
sition 1899 which was previously shown to emerge fre-
quently either alone or in combination with stop codon
mutations at position 1896 during IFNa-induced serocon-
version to anti-HBe, in particular in patients who did not
clear the virus completely (Gu¨nther et al., 1992). However, in
agreement with the functional data presented here, so far
no measurable effect of this mutation on HBV replication
and gene expression has been established (Hasegawa et
al., 1994; Yuan et al., 1995; Miska, 1996). Furthermore, the
presence of a virus population with a pre-S2 deletion in the
pretreatment phase, its disappearance during treatment,
and the reappearance of a population nearly identical to the
initial HBV population is an interesting observation. It sug-
gests that dynamic changes in the circulating HBV pool
may occur due to outgrowth of preexisting minor popula-
tions that perhaps reside in particular cells or organs for
long periods of time.
Recently, cytokine-mediated intracellular mechanisms
inhibiting wild-type HBV, one acting on a posttranscrip-
tional HBV RNA element and a second on the core
particle and/or the associated HBV DNA, were reported
(Tsui et al., 1995; Guidotti et al., 1996) and could be
responsible for virus clearance in vivo (Jilbert et al., 1992;
Kajino et al., 1994). These findings prompted us to test
whether IFNa-resistant viruses, for example, with muta-
tions in corresponding response elements, have been
FIG. 8. Functional analysis and IFNa susceptibility of HBV genome populations isolated from the patient during follow-up and comparison with a
wild-type genome. Full-length HBV genomes were amplified by PCR and transfected into HuH7 cells without cloning. (A) Southern blot analysis of
intracellular replicative HBV DNA intermediates. Treatment of the transfected cells with 500 U IFNa/ml culture medium is indicated. The ratios of the
HBeAg, HBsAg, and HBV DNA levels with and without IFNa treatment are given below the blot (mean and SD of two transfection experiments). SEAP
expressed from a cotransfected reporter plasmid did not respond to IFNa. SEAP values were used for normalization of the HBV parameters. The
3.2-kb double-strand (ds) and single-strand (ss) positions of the marker (M) are indicated. (B) HBeAg and (C) HBsAg values without IFNa treatment
(S/N ratio, mean and SD of two transfection experiments) as determined by enzyme immunoassays [AxSYM (Abbott)].
156 GU¨NTHER ET AL.
selected during the long-term IFNa treatment and ac-
count for virus persistence. This hypothesis was sup-
ported by previous observations of interferon-resistant
strains of measles, herpes simplex, and lymphocytic
choriomeningitis virus which have an increased ten-
dency to establish virus persistence (Carrigan and Kehl-
Knox, 1990; Su et al., 1990; Moskophidis et al., 1994). The
data presented demonstrate that all virus populations
present during the observation period and wild-type vi-
rus were similarly sensitive to intracellular inhibition by
IFNa in vitro. A possible explanation may be that the
cytokine-activated antiviral state targets structures or
functions which cannot be changed by mutations without
loss of vital virus functions. If this is true, HBV cannot
escape intracellular antiviral effector mechanisms and,
therefore, uses strategies to prevent their activation such
as downregulation of cytokine expression (Pirovino et al.,
1986; Whitten et al., 1991) and of HBV-specific cellular
immunity (Ferrari et al., 1990; Milich et al., 1990; Jung et
al., 1991; Penna et al., 1991; Rehermann et al., 1995). In
conclusion, our data argue for roles of a reduced HBe
expression level and modulation of HBc/e B-cell antige-
nicity rather than interferon resistance in virus persis-
tence in the patient studied.
MATERIALS AND METHODS
The patient
The patient studied (male, 51 years) acquired HBV
infection in 1981 in Cuba and developed a hepatitis B
surface antigen (HBsAg)-, HBeAg-, and anti-HBc-positive
chronic hepatitis B. Chronic persistent hepatitis was di-
agnosed histologically in 1983, which progressed to CAH
in 1989 and 1990. He was treated from September 1989
to August 1990 and from October 1990 to January 1991
with 3 Mio U and from January 1991 to March 1991 with
10 Mio U recombinant IFNa2b three times per week (Fig.
1). Serological markers of HBV infection were deter-
mined by commercial kits (Sorin, Saluggia, Italy; Abbott,
Wiesbaden, FRG). Serum HBV DNA titre was determined
semiquantitatively by dot blot hybridization and nested
PCR (Gu¨nther et al., 1992). The patient was negative for
markers of hepatitis C virus, hepatitis delta virus, and
hepatitis A virus infection. The HLA type of the patient
was A1, B8, Cw7, Bw6, DR3, DR52, and DQ2.
Detection of HBeAg-immune complexes
As described previously (Miles et al., 1993), serum (30 ml)
was mixed with 30 ml 1.5 M glycine–HCl (pH 1.5) and
incubated for 1.5 h at 37°C. It was then neutralized with 160
ml 1.5 M Tris–HCl (pH 7.5) and incubated for 2 h at room
temperature, and 200 ml thereof was subsequently tested
for the presence of HBeAg with the ETI-EBK test kit (Sorin).
Isolation of DNA from serum
From each serum sample, 300 ml was incubated at
65°C for 4 h in 20 mM Tris–HCl (pH 8.0), 10 mM EDTA,
0.1% SDS, and 0.8 mg proteinase K/ml. The DNA was
then extracted with phenol, subsequently with chloro-
form, and precipitated with ethanol using 20 mg tRNA as
carrier. The pellet was dissolved in 20 ml H2O.
Amplification of complete virion-encapsidated HBV
genomes and C-gene sequences
Full-length HBV genomes were amplified by PCR
(Gu¨nther et al., 1995) with serum HBV DNA in 50-ml
Expand High Fidelity PCR assays (Boehringer Mann-
heim, FRG) containing 1.5 mM MgCl2, 200 mM dNTP, 2.6
U Taq and Pwo polymerase mixture, and 0.3 mM primers
P1 and P2 (P1: 59-CCGGAAAGCTTGAGCTCTTCTTTT-
TCACCTCTGCCTAATCA; P2: 59-CCGGAAAGCTTGAGC-
TCTTCAAAAAGTTGCATGGTGCTGG; HBV homologous
sequences: 1821–1841 and 1825–1806, respectively; Sst I
sites used for cloning and SapI sites cleaved before
direct transfection are underlined). The PCR was per-
formed with hot-start and for 40 cycles with denaturation
at 94°C for 40 s, annealing at 60°C for 1.5 min, and
elongation at 68°C for 3 min with an increment of 2 min
after every 10 cycles in a Robocycler (Stratagene). Sub-
genomic fragments comprising the C-gene were ampli-
fied with primers P3/P4 (P3: 1767–1788, 59-TTTGTACTAG-
GAGGCTGTAGGC; P4: 2510–2487, 59-AGGTACAGTAGAA-
GAATAAAGCCC).
Direct sequencing of PCR products
Both DNA strands of the PCR products were completely
sequenced using overlapping single-stranded fragments gen-
erated by asymmetric PCR using 1 ml of PCR product in 100 ml
buffer with Taq polymerase (20 cycles) and different pairs of
primers in 2:100 and 100:2 molar ratios. The following primer
pairs were used: P3/P4 and P1/P4 (for sequences see above),
P5/P6 (P5: 2215–2237, 59-TTCTTGTCTCACTTTTGGAAGAG;
P6: 202–179, 59-CTGTAACACGAGAAGGGGTCCTAG), P7/P8
(P7: 2744–2767, 59-CTATTTACACACTCTATGGAAGGC; P8:
1121–1100, 59-AGAAAGGCCTTGTAAGTTGGCG), P9/P2 (P9:
818–839, 59-CTTTGGGTATACATTTAAACCC).
The reaction products were extracted with phenol/
chloroform, purified by centrifugation through Sephadex
G-50 columns, precipitated with ethanol, and dissolved
in water. Direct sequencing was performed using a
Sequenase kit (USB, Cleveland, OH) and the following
32P-labeled plus-strand primers: P10 (67–90, 59-CTCC-
AGTTCAGGAACAGTAAACCC); P11 (368–390, 59-TATCG-
CTGGATGTGTCTGCGGCG); P12 (634–656, 59-ATTCCTAT-
GGGAGTGGGCCTCAG); P9; P13 (1019–1040, 59-CTGCC-
CCTTTTACACAATGTGG); P14 (1266–1286, 59-CCATACT-
GCGGAACTCCTAGC); P15 (1505–1527, 59-CGTTCCGAC-
CGACCACGGGGCGC); P16 (1725–1749, 59-AAAGACT-
GGGAGGAGTTGGGGGAGG); P3; P2; P17 (1928–1950, 59-
GGAGCTACTGTGGAGTTACTCTC); P5; P18 (2442–2462,
59-CTCAATGTTAGTATTCCTTGG); P7; P19 (3039–3061, 59-
GGGGTGGAGCCCTCAGGCTCAGG) and minus-strand
primers: P6; P20 (477–455, 59-GGACAAACGGGCAACAT-
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ACCTTG); P21 (738–716, 59-ATAACTGAAAGCCAAACAG-
TGGG); P22 (990–970, 59-ACATACTTTCCAATCAATAGG);
P8; P23 (1394–1372, 59-GCAGCACAGCCTAGCAGCCATGG);
P24 (1620–1599, 59-CGGTGGTCTCCATGCGACGTGC);
P25 (2043–2021, 59-CAATGCTCAGGAGACTCTAAGGC);
P26 (2322–2300, 59-GATAGGATAGGGGCATTTGGTGG);
P4; P27 (2715–2697, 59-GATGTTCTGGATAATAAGG); P28
(2957–2935, 59-TTGGGATTGAAGTCCCAATCTGG); P29
(3134–3112, 59-GGGGTAGGCTGCCTTCCTGACTG).
All amplification and sequencing primers were de-
signed with sequences highly conserved among all HBV
genotypes. Sequences derived from corresponding plus
and minus strands were identical and full-length genome
PCR primers P1/P2 perfectly matched to HBV DNA as
verified by sequencing of C-gene fragments overlapping
their binding sites. These controls rule out sequence
artifacts by selective binding of amplification or sequenc-
ing primers to a specific virus subpopulation. The extent
of sequence heterogeneity at a specific position was
estimated visually from the signal intensity of the corre-
sponding bands. Potential HBV protein binding sites for
the HLA molecules of the patient were searched for by
using a computer program which is based on the known
peptide anchor motifs for HLA-A1 (- -D/E- - - - -Y) and
HLA-B8 (- - K/R - K/R - - - L) (Rammensee et al., 1995).
Cloning and sequencing of complete C-genes
A small aliquot of the PCR fragments generated with
primers P3/P4 was cloned into vector pCR II (Invitrogen,
Leek, The Netherlands). The pre-C/C-gene of several
clones was sequenced using vector- and HBV-specific
primers (P4 and P17). Five representative pre-C/C-gene
inserts were released from the vector by EcoRI cleavage
and cloned into eukaryotic expression vector pRK5
downstream of the cytomegalovirus (CMV) immediate
early promoter (pRK5-HBe constructs).
Preparation of amplified HBV genomes for direct
transfection
The 3.2-kb HBV genomes amplified from serum of the
patient or from 0.3 pg plasmid-integrated wild-type HBV
DNA (Galibert et al., 1979) were gel-purified with the
QIAquick Gel Extraction Kit (Qiagen, Hilden, FRG). Sub-
sequently, 0.5 ml (1%) thereof was reamplified for 20
cycles in 5 3 50 ml assays using the same primers and
conditions as above. The amplification products were
pooled, extracted with phenol:chloroform (1:1) and chlo-
roform, and washed five times with water in Centricon-
100 concentrators (Amicon, Beverly, MA) to remove re-
sidual dNTPs and primers. The DNA was then quantified
spectrophotometrically.
Transfection of HBV DNA
For direct transfection of amplified 3.2-kb HBV ge-
nomes, the heterologous primer sequences were
cleaved off with 1.5 U SapI/mg PCR product (New En-
gland Biolabs) for 12 h. Transfection of 5 mg cleaved
DNA, 10 mg pRK5-HBe DNA, or pUC19 DNA as mock
control per 50-mm petri dish was carried out according
to the calcium phosphate precipitation method. HuH7
cells were plated at a density of 1.2 3 106 cells/50-mm
petri dish. Medium was changed 1 day after transfection
and 500 U IFNa/ml medium was added where appropri-
ate. Cells were harvested 3–4 days later. Two or more
independent transfection experiments were performed
with each construct. HBeAg and HBsAg values were
determined in the supernatant by enzyme immunoas-
says [AxSYM (Abbott)]. Transfection efficiency was mea-
sured by cotransfection of 1 mg reporter plasmid ex-
pressing secreted alkaline phosphatase (SEAP) and de-
termination of SEAP enzymatic activity in the cell culture
supernatant (Cullen and Malim, 1992).
Analysis of variant HBe antigenicity
The supernatants of cells transfected with pRK5-HBe
constructs and pUC19 as a negative control were ana-
lyzed with commercial HBeAg test kits [HBe rDNA and
AxSYM HBe (Abbott)] according to the manufacturer’s
instructions. None of the HBe variants displayed HBc
antigenicity as tested with anti-HBe on the solid phase
and anti-HBc as conjugate (Organon Teknika). In addi-
tion, a polyclonal anti-HBe mix obtained from the serum
of HBV-infected donors (Organon Teknika) or monoclonal
antibody (mAb) anti-HBc/e[4] were coated on the solid
phase of a microtiter plate (5 mg/ml) and incubated with
supernatant for 2 h at 37°C. After washing, the bound
HBeAg was enzymatically detected with peroxidase-la-
beled mAb anti-HBe[1] diluted 1:8,000. Anti-HBe[1] rec-
ognizes the HBe carboxy terminus and anti-HBc/e[4]
recognizes the HBe1 and the overlapping HBc determi-
nant (W. Paulij, unpublished data).
Competitive assay for reactivity of anti-HBe from the
patient with HBe variants
Supernatants of pRK5-HBe-transfected cells were di-
luted and tested with a commercial HBeAg test which
uses human polyclonal anti-HBe on solid phase as well
as for detection (IMx, Abbott). Dilutions which resulted in
signal to noise ratios (S/N) of about 20 (HBe variant 2,
1:10; HBe variant 6, 1:50; HBe variant 10, 1:50; HBe
variant 16, 1:10; HBe variant 18, 1:20) were chosen for
competition experiments. Anti-HBe-positive sera of the
patient (diluted 1:5 or 1:10 and 1:50 or 1:100) were added
to the assay to inhibit binding of the diluted HBe to the
heterologous polyclonal anti-HBe on the solid phase
(negative control, without HBe and serum; positive con-
trol, without serum). After incubation for 2 h at room
temperature HBe bound by the solid phase was detected
using the IMx system. The fraction of solid phase-bound
HBe (FHBe) was calculated as FHBe5(S/Ntest sample-S/
Nnegative control)/(S/Npositive control-S/Nnegative control).
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Peptide-based direct assay for reactivity of anti-HBc/e
from the patient with the HBc/e1 epitope
The following HPLC-purified HBc/e peptides covering
the HBc/e1 epitope were used: peptide 1, core residues
69–99, ATWVGANLEDPASRDLVVSYVNTNMGLKFRQ; pep-
tide 2, identical to peptide 1 except E(77)3 Q and S(87)3
T exchanges; peptide 3, identical to peptide 1 except
D(83) 3 E and T(91) 3 I exchanges. They were coated
overnight onto the surface of an immunoplate (Maxisorp;
Nunc) at a concentration of 10 mg/ml in 0.1 M carbonate
buffer (pH 9.5). Plates were blocked with 1% bovine
serum albumin (BSA)–0.1% Tween 20 in PBS for 1 h,
washed, and incubated for 1 h at 37°C with serum of the
patient diluted 1:10 to 1:1280 in 1% BSA. After washing,
IgG antibodies bound to the solid phase were detected
using peroxidase-labeled anti-human-IgG antibodies (0.2
mg/ml) in 1% BSA for 1 h at 37°C. Four independent
experiments were performed.
Purification of HBV DNA from intracellular core
particles and Southern blot analysis
Cells were washed and lysed in 1 ml lysis buffer [50
mM Tris–HCl (pH 7.4), 1 mM EDTA, 1% NP-40] per dish.
The lysat was vortexed and incubated on ice for 15 min
and nuclei were pelleted by centrifugation. The superna-
tant was adjusted to 10 mM MgCl2 and treated with 100
mg DNaseI/ml for 30 min at 37°C. EDTA was added to a
final concentration of 25 mM. Proteins were digested
with 0.5 mg proteinase K/ml and 1% SDS for 2 h at 37°C.
Nucleic acids were phenol:chloroform (1:1) extracted
and ethanol-precipitated after adding 20 mg tRNA. DNAs
were separated on an 1.5% agarose gel, blotted onto
Hybond N nylon membranes (Amersham), and hybrid-
ized with a 32P-labeled full-length HBV probe. Autora-
diography was analyzed with FUJIX BAS 2000 (Fuji, To-
kyo, Japan) and signals were quantified using TINA soft-
ware (Raytest, Straubenhardt, Germany).
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